Skip to search formSkip to main contentSkip to account menu

TLR9 Agonist SD-101

Known as: ISS-ODN SD-101, SD-101 
A proprietary oligonucleotide with immunostimulatory activity. Immunostimulatory phosphorothiolate oligodeoxyribonucleotide SD-101 targets Toll-Like… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
2016
2016
Abstract 2322: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade
The induction of tumor specific T cell exhaustion by the PD-1/PDL-1 pathway is an important mechanism of immune escape in cancer… 
2015
2015
EB drug has significant medical, market potential
Scioderm Inc. has released data from its recently completed phase 2b clinical trial — and plans for a phase 3 trial — on its… 
Review
2013
Review
2013
Biosimilars legislation state by state
947 the breakthrough-designated compounds, SD-101 is an orphan, and thus already fasttracked in terms of regulatory review. But… 
Review
2013
Review
2013
Otsuka snaps up cancer drugmaker Astex
volume 31 NumBeR 11 NovemBeR 2013 nature biotechnology completing a second phase 2, the company went to FDA with data from one… 
2012
2012
Metabolic and cardiovascular consequences of OSA II P 3863 Usefulness of SD-101 for screening of sleep apnea syndrome
printing supported by . Visit Chiesi at Stand B2.10 TUESDAY, SEPTEMBER 4TH 2012 Methods: Multicenter-randomized study. 210…